European Post Pandemic Recovery Equity

Post Pandemic Recovery Equity appears to be a European special purpose acquisition company (SPAC) referenced in SEC materials as a vehicle sponsored by Swiss Growth Forum. Based on available evidence, it was formed as an investment and merger vehicle rather than as an operating biotechnology, pharmaceutical, or healthcare company. The entity was discussed in connection with a potential merger involving European rights to crofelemer/Mytesi, but there is no clear evidence that the SPAC itself developed drugs, operated a therapeutic pipeline, or functioned as a life sciences company. Accordingly, it is best characterized as a financial acquisition vehicle rather than a biotech operating company.